from the rapidly evolving industry of oncology investigate, exact and efficient mutation screening is critical for producing focused therapies. The KRAS companies System performs a pivotal part Within this landscape by supplying thorough solutions for KRAS mutation profiling and Examination. KRAS mutations, present in approximately ninety five% of